« Return to News | Awards & Advancement

Celerion receives ANVISA certification

Friday, June 10, 2011 11:33 AM

Lincoln, Neb.-based Celerion, a provider of early-stage drug development solutions, has announced that its clinical research operations in Belfast, Northern Ireland, and its clinical research and bioanalytical services operations in Lincoln, Neb., have been certified by the Brazilian National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária – ANVISA). 

ANVISA provides regulatory approval for drugs and other products seeking to enter the large and growing Brazilian market.  ANVISA-certified service providers are qualified to help clients clear a key hurdle to access one of the fastest-growing major pharmaceutical markets in the world. 

“The approval of ANVISA continues to demonstrate the high-quality work done at Celerion,” said Susan Thornton, president and CEO.  “By earning ANVISA certification to conduct early clinical studies and bioanalytical research for compounds destined for Brazil, Celerion is now able to better serve our clients’ growing needs in this high-growth, emerging market.”

In addition to ANVISA certification, Celerion’s Belfast facility also has been certified by the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA). The facility has received both standard and supplementary accreditation from the MHRA, which certifies that the general standards for study participant safety and access to emergency medical response have been met.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.